Viral Hepatitis B Vaccine
In 2001, the FDA approved a combination of hepatitis A and hepatitis B vaccine marketed as the trade name Twinrix. This combination allows adults to receive protection against both forms of hepatitis with three injections instead of five. Hepatitis B vaccine is also present in PEDIARIX and Engerix-B combination vaccines.
The hepatitis B vaccine protects against infection with the hepatitis B virus. Everyone who is under 18 years of age should get hepatitis B vaccine. Unimmunized children younger than 18 years may begin the series at any age. Adults should get the hepatitis B vaccine if they are at risk for infection.
Indications for use
- Dialysis nurses
- Dialysis patients
- Health care workers
- Infants with hepatitis B infected mothers
- Institutionalized patients
- Intravenous drug users
- Male homosexuals.
- Sexually promiscuous persons
- Geographical area; your risk is also higher if your parents were born in:
- Southeast Asia
- Amazon Basin in South America
- Pacific Islands
- Middle East
Those who have had a serious reaction to baker's yeast in the past should not receive this vaccine.
Complete immunity to hepatitis B virus will require the administration of three boosters:
- In most cases the first booster may administered anywhere from birth to through the second month of life. Infants born to hepatitis B infected mothers should receive vaccine and 0.5 mL of hepatitis B immune globulin (HBIG) within 12 hours of birth at separate sites.
- The second booster should be administered at least one month after the first dose. Infants born to hepatitis B infected mothers should receive the second dose at least one month after the first dose.
- The third booster should be given at least 2 months after the second, but not before six months of age. Infants born to hepatitis B infected mothers should receive their third dose at least four months after the first and two months after the second, but not before 6 months of age.
- Illness may require a shot to be delayed. Only your doctor can make this determination.
- Soreness at the vaccination site (1 out of 11 children)
- Mild to moderate fever ( 1 out of 14 children)
Continue to Viral Hepatitis B Outlook
- Murdoch DL, Goa K, Figgitt DP. Combined hepatitis A and B vaccines: a review of their immunogenicity and tolerability. Drugs. 2003;63(23):2625-49. 
- Oncu S, Oncu S, Sakarya S. Hepatitis A and B seropositivity among medical students. Health Policy. 2005 Sep 28;74(1):39-45. 
- Papatheodoridis GV, Hadziyannis SJ. Review article: current management of chronic hepatitis B. Aliment Pharmacol Ther. 2004 Jan 1;19(1):25-37. 
- Rich JD, Ching CG, Lally MA, Gaitanis MM, Schwartzapfel B, Charuvastra A, Beckwith CG, Flanigan TP. A review of the case for hepatitis B vaccination of high-risk adults. Am J Med. 2003 Mar;114(4):316-8. 
- Rischitelli G, Harris J, McCauley L, Gershon R, Guidotti T. The risk of acquiring hepatitis B or C among public safety workers: a systematic review. Am J Prev Med. 2001 May;20(4):299-306. 
- Robins GW, Scott LJ, Keating GM. Peginterferon-alpha-2a (40kD): a review of its use in the management of patients with chronic hepatitis B. Drugs. 2005;65(6):809-25.